Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | GABRP | O00591 | 1/20 | 0.42 |
| ▸ | GABRD | O14764 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12051172 | 0.99 | RPS6KB1 (0.48) | RPS6KB1ALDH1A1NPSR1ATMSMN1; SMN2 | |
| SCHEMBL3747860 | 0.87 | L3MBTL1 (0.56) | ALDH1A1L3MBTL1GAASCN5ASCN9A | |
| SCHEMBL3747486 | 0.83 | ALDH1A1 (0.47) | RPS6KB1ALDH1A1NPSR1ATMSMN1; SMN2 | |
| SCHEMBL12051166 | 0.82 | ALDH1A1 (0.49) | RPS6KB1ALDH1A1NPSR1ATMSMN1; SMN2 | |
| SCHEMBL3750336 | 0.80 | RPS6KB1 (0.42) | RPS6KB1ALDH1A1NPSR1ATMSMN1; SMN2 | |
| SCHEMBL12051162 | 0.78 | KCNH2 (0.53) | RPS6KB1ALDH1A1NPSR1ATMSMN1; SMN2 | |
| SCHEMBL28267709 | 0.77 | ALDH1A1 (0.51) | RPS6KB1ALDH1A1NPSR1ATMSMN1; SMN2 | |
| SCHEMBL13635205 | 0.72 | ALDH1A1 (0.51) | RPS6KB1ALDH1A1NPSR1ATMSMN1; SMN2 | |
| SCHEMBL13011205 | 0.72 | ALDH1A1 (0.51) | RPS6KB1ALDH1A1NPSR1ATMSMN1; SMN2 | |
| SCHEMBL13011202 | 0.72 | ALDH1A1 (0.51) | RPS6KB1ALDH1A1NPSR1ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838537-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838537-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| US-7838537-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-11-23 | — | — | US | disclosed |
| EP-1587585-B1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES | BOEHRINGER INGELHEIM INT (DE) | 2008-10-15 | — | — | EP | disclosed |
| US-20080119490-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119490-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-20080119490-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-05-22 | — | — | US | disclosed |
| US-7323470-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-29 | — | — | US | disclosed |
| US-7323470-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-29 | — | — | US | disclosed |
| US-7323470-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-01-29 | — | — | US | disclosed |
| US-7098231-B2 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-29 | — | — | US | disclosed |
| US-20060189672-A1 | Viral polymerase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-08-24 | — | — | US | disclosed |
| EP-1587585-A1 | ACYLSULFONAMIDE COMPOUNDS AS INHIBITORS OF RNA-DEPENDENT RNA (VIRAL) POLYMERASES | Boehringer Ingelheim International GmbH (DE) | 2005-10-26 | — | — | EP | disclosed |
| US-20040186125-A1 | E.g , 3-cyclohexyl-2-furan-3-yl-1Hindole-5-carboxylic acid; hepatitis C viricides that target RNA dependent RNA polymerases (Ns5B) in mammals, an enzyme essential to viral replication; used in conjunction with an mmunomodulatory agent, such as beta -, delta - gamma -, and omega -interferon | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-09-23 | — | — | US | disclosed |
| WO-2004064925-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2004-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189672-A1 | Viral polymerase inhibitors | POLM, POLR2A, POLR2H | RPS6KB1 597/4885ALDH1A1 1245/4885NPSR1 2914/4885 |
| US-20080119490-A1 | Viral Polymerase Inhibitors | POLM, POLR2H, POLR2A | RPS6KB1 572/4885ALDH1A1 1320/4885NPSR1 2644/4885 |
| US-20040186125-A1 | E.g , 3-cyclohexyl-2-furan-3-yl-1Hindole-5-carboxylic acid; hepatitis C viricides that target RNA dependent RNA polymerases (Ns5B) in mammals, an enzyme essential to viral replication; used in conjunction with an mmunomodulatory agent, such as beta -, delta - gamma -, and omega -interferon | IFNAR1, IFNG, EIF2AK2 | RPS6KB1 1395/4885ALDH1A1 938/4885NPSR1 3760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.